ERBB2 and breast carcinoma: The ERBB2 gene and erbB-2 protein status (gene amplification/protein overexpression) are considered useful markers for predicting the response to a specific cancer therapy, and analysis of these markers is mandatory for the identification of breast cancer patients that are amenable to trastuzumab treatment.